BRD2 and myeloid sarcoma: The knowledge that the IgG antibody response to EBV is usually lifelong, without showing any significant decline over time,36 and that the anti-MeV IgG response in patients with MS tends to increase over time in response to both natural infection and vaccination,3 suggest that the decreased antibody levels may be associated with NAT therapy.